Table 1.
Sociodemographic, clinical, endometriosis-related and psychosocial characteristics in the groups CPP and NOPAIN.
| Group | |||||
|---|---|---|---|---|---|
| N | CPP (n = 50) 1 | NOPAIN (n = 50) 1 | p-Value | Effect Size 1 | |
| Sociodemographic data | |||||
| Age | 99 | 28.79 (5.59) | 32.71 (6.26) | 0.001 2,7 | d = 0.66 |
| Socioeconomic status | 90 | 10.65 (8.81; 12.04) | 11.80 (10.60; 13.50) | 0.008 3,7 | d = 0.57 |
| Relationship | 100 | 36 (72%) | 43 (86%) | 0.140 4,7 | |
| Children | 100 | 7 (14%) | 12 (24%) | 0.154 4,6 | |
| University degree | 98 | 22 (45%) | 24 (49%) | 0.840 4,7 | |
| Clinical characteristics | |||||
| Time since first diagnosis (years) | 99 | 2.07 (1.34; 4.65) | 3.76 (2.00; 7.21) | 0.008 3,7 | d = 0.56 |
| Number of surgeries | 99 | 2.00 (1.00; 3.00) | 1.00 (1.00; 2.00) | 0.051 3,7 | |
| Hormonal treatment | 100 | 34 (68%) | 30 (60%) | 0.532 4,7 | |
| Hormones: Mode of intake 8 | 63 | - | - | 0.525 4,7 | |
| Hormones: Substance 9 | 100 | - | - | 0.708 5,7 | |
| Hormones: Tolerance | 54 | 2.00 (2.00; 3.00) | 3.00 (3.00; 3.00) | <0.001 3,7 | d = 0.96 |
| Hormones: Pain reduction | 52 | 2.00 (1.50; 3.00) | 5.00 (4.00; 5.00) | <0.001 3,6 | d = 1.85 |
| Infertility | 100 | 18 (36%) | 15 (30%) | 0.335 4,6 | |
| Other medical condition | 100 | 27 (54%) | 21 (42%) | 0.158 4,6 | |
| Additional persistent pain | 100 | 43 (86%) | 14 (28%) | <0.001 4,6 | OR = 15.80 |
| Endometriosis | |||||
| Pelvic pain days per month | 100 | 30.50 (25.00; 31.00) | 1.00 (0.00; 2.50) | <0.001 3,7 | d = 3.40 |
| Dysmenorrhea | 99 | 32 (65%) | 17 (34%) | 0.002 4,6 | OR = 3.65 |
| Primary dysmenorrhea | 38 | 29 (88%) | 12 (80%) | 0.378 5,6 | |
| Pain intensity | 98 | 6.00 (0.00; 8.00) | 0.00 (0.00; 1.00) | <0.001 3,7 | d = 1.05 |
| Pain intensity: treatment-goal | 98 | 3.00 (0.00; 4.00) | 0.00 (0.00; 1.25) | <0.001 3,7 | d = 0.83 |
| Pain intensity: discrepancy | 97 | 2.00 (0.00; 4.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 1.40 |
| Non-menstrual cyclical pelvic pain | 98 | 30 (63%) | 10 (20%) | <0.001 4,6 | OR = 6.67 |
| Duration (years) | 36 | 10.00 (5.00; 15.00) | 7.00 (4.75; 11.00) | 0.351 3,7 | |
| Pain intensity | 99 | 4.00 (0.00; 6.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 1.08 |
| Pain intensity: treatment-goal | 99 | 2.00 (0.00; 3.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 0.85 |
| Pain intensity: discrepancy | 98 | 2.00 (0.00; 3.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 1.22 |
| Non-cyclical pelvic pain | 100 | 50 (100%) | 11 (22%) | <0.001 4,6 | |
| Duration (years) | 48 | 6.00 (3.00; 10.25) | 5.00 (0.85; 7.25) | 0.173 3,7 | |
| Pain intensity | 97 | 5.00 (4.00; 6.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 3.11 |
| Pain intensity: treatment-goal | 97 | 2.00 (1.00; 3.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 1.49 |
| Pain intensity: discrepancy | 96 | 3.00 (2.00; 3.50) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 2.88 |
| Duration of CPP (years) | 42 | 2.25 (1.50; 5.00) | - | - | |
| Painful sexual intercourse | 100 | 46 (92%) | 27 (54%) | <0.001 4,7 | OR = 9.80 |
| Pain intensity | 99 | 5.00 (3.00; 7.00) | 0.00 (0.00; 2.00) | <0.001 3,7 | d = 1.82 |
| Pain intensity: treatment-goal | 99 | 1.50 (1.00; 3.00) | 0.00 (0.00; 1.00) | <0.001 3,7 | d = 0.83 |
| Pain intensity: discrepancy | 99 | 3.00 (2.00; 4.00) | 0.00 (0.00; 0.13) | <0.001 3,7 | d = 1.73 |
| Dyschezia | 100 | 40 (80%) | 23 (46%) | <0.001 4,7 | OR = 4.70 |
| Pain intensity | 99 | 4.00 (2.00; 5.00) | 0.00 (0.00; 2.00) | <0.001 3,7 | d = 1.15 |
| Pain intensity: treatment-goal | 98 | 2.00 (0.00; 2.00) | 0.00 (0.00; 1.25) | <0.001 3,7 | d = 0.76 |
| Pain intensity: discrepancy | 98 | 2.00 (0.00; 3.00) | 0.00 (0.00; 1.00) | <0.001 3,7 | d = 0.98 |
| Dysuria | 100 | 26 (52%) | 7 (14%) | <0.001 4,7 | OR = 6.65 |
| Pain intensity | 100 | 0.75 (0.00; 4.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 0.72 |
| Pain intensity treatment-goal | 99 | 0.00 (0.00; 2.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 0.66 |
| Pain intensity: discrepancy | 99 | 0.00 (0.00; 2.00) | 0.00 (0.00; 0.00) | <0.001 3,7 | d = 0.58 |
| Psychosocial characteristics | |||||
| Affected career | 98 | 24 (49%) | 16 (33%) | 0.075 4,7 | |
| Affected relationship | 95 | 42 (89%) | 24 (50%) | <0.001 4,7 | OR = 8.4 |
1 Data presented as M (SD), Median (percentile 25; percentile 75) or frequencies (%), d = Cohen’s d, OR = odds ratio. 2 t-test, 3 Mann–Whitney U-test, 4 χ2-test, 5 Fisher’s exact test, 6 one-tailed testing, 7 two-tailed testing. 8 mode of intake: non-stop: CPP = 28 (85%), NOPAIN = 23 (77%); cyclical: CPP = 5 (15%), NOPAIN = 7 (23%). 9 substance: no hormonal treatment: CPP = 17 (34%), NOPAIN = 20 (40%); COC: CPP = 9 (18%), NOPAIN = 10 (20%); desogestrel: CPP = 3 (6%), NOPAIN = 6 (12%); dienogest: CPP = 15 (30%), NOPAIN = 11 (22%); GnRHA: CPP = 3 (6%), NOPAIN = 1 (2%); hormone-releasing IUD: CPP = 3 (6%), NOPAIN = 2 (4%).